ArticleScience translational medicine2022
Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.The Journal of experimental medicine · 2024Trial
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.Journal of virology · 2026Article
- Article
- A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.medRxiv : the preprint server for health sciences · 2026Article
- Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).medRxiv : the preprint server for health sciences · 2026Article
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Article
- Prefusion structure, evasion and neutralization of HSV-1 glycoprotein B.Nature microbiology · 2025Article
- Development and characterization of a human papillomavirus-based nanoparticle carrier for heterologous vaccine antigens.Scientific reports · 2025Article
- Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques.Cell reports · 2025Article
- Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates.Science translational medicine · 2025Article
- Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.Frontiers in microbiology · 2025Article
- Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.Journal of virology · 2024Article
- Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.Science immunology · 2024Article
- Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.Science immunology · 2024Article
- Article
- Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.Cell host & microbe · 2024Article
- Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.Cell · 2024Article
- Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.bioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 7 institutions in 1 country.
Kevin O SaundersDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-7399-7954
Robert J EdwardsDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-4446-1194
Kedamawit TilahunDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-2107-1580
Kartik ManneDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-7218-4852
Xiaozhi LuDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-2517-6331
Derek W CainDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-5988-6729
Kevin WieheDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-9933-9618
Wilton B WilliamsDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-2970-7259
Katayoun MansouriDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-6232-7330
Giovanna E HernandezDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-5498-3469
Laura SutherlandDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-4119-3884
Richard ScearceDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-6361-3758
Robert ParksDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-6259-7610
Maggie BarrDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Todd DeMarcoDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Chloe M EaterDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-4272-8409
Amanda EatonDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-3064-2947
Georgeanna MortonBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-6675-8004
Benjamin MildenbergBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-0645-6047
Yunfei WangDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-3205-6338
R Wes RountreeDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-5183-6949
Mark A Tomai3M Corporate Research Materials Lab, 3M Company, St. Paul, MN 55144, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA 98102, USA.ORCID 0000-0002-4644-2619
M Anthony MoodyDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-3890-5855
S Munir AlamDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-0941-0703
Sampa SantraBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-8796-1714
Mark G LewisBioqual Inc., Rockville, MD 20850-3220, USA.ORCID 0000-0001-7852-0135
Thomas N DennyDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
George M ShawDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2338-4532
David C MontefioriDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Priyamvada AcharyaDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-0089-277X
Barton F HaynesDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-7643-9023
Duke Medical Center · USBeth Israel Deaconess Medical Center · US3M (United States) · USBioqual · USDuke University · USInfectious Disease Research Institute · USUniversity of Pennsylvania · US
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MNonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7MHIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesR01AI165080 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2021 to 2026
$6.6MReverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignR01AI160607 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2021 to 2024
$3.2MNIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI160607NIAID NIH HHS R01 AI165080NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI144371
Abstract
A successful HIV-1 vaccine will require induction of a polyclonal neutralizing antibody (nAb) response, yet vaccine-mediated induction of such a response in primates remains a challenge. We found that a stabilized HIV-1 CH505 envelope (Env) trimer formulated with a Toll-like receptor 7/8 agonist induced potent HIV-1 polyclonal nAbs that correlated with protection from homologous simian-human immunodeficiency virus (SHIV) infection. The serum dilution that neutralized 50% of virus replication (ID
Indexed as
AIDS VaccinesCommunicable DiseasesHIV-1Simian Immunodeficiency VirusAnimalsAntibodies, NeutralizingAntibodies, ViralHumansImmunizationMacaca mulattaVaccinationAIDS VaccinesAntibodies, NeutralizingAntibodies, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.